Rev-erbα can regulate the NF-κB/NALP3 pathway to modulate lipopolysaccharide-induced acute lung injury and inflammation

Rev-erbα reduces IL-1β production and lung injury following an injection of lipopolysaccharide (LPS).

• Intraperitoneal injection of LPS can induce progressive lung injury and inflammation.
• Interleukin-1β (IL-1β) is associated with exacerbating inflammation and is activated by the NALP3 inflammasome.
• Rev-erbα is linked to a decrease in IL-1β levels and subsequent lung injury in response to LPS.
• The reduction of lung injury by Rev-erbα involves the NF-κB/NALP3 signaling pathway.
• These findings suggest that targeting Rev-erbα may offer a new therapeutic approach for acute lung injury.

AI simplified